AGENUS INC Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31)
AGENUS INC (AGEN) reported Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) of 220.00% for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-18.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition · last filed 2013-03-18
- AGENUS INC employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition (deprecated 2012-01-31) for fiscal 2012 was 220.00%.
pure
| Period end | Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) 12 month |
|---|---|
| 2012-12-31 | 220.00% 10-K · filed 2013-03-18 |
Y
| Period end | Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) 6 month | Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) 9 month |
|---|---|---|
| 2012-09-30 | 2.40 Y 10-Q · filed 2012-11-07 | |
| 2012-06-30 | 2.60 Y 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |